Metformin enhances the osteogenic activity of rat bone marrow mesenchymal stem cells by inhibiting oxidative stress induced by diabetes mellitus: an in vitro and in vivo study
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The purpose of this study was to determine whether metformin (MF) could alleviate the expresssion of reactive oxygen species (ROS) and improve the osteogenic ability of bone marrow mesenchymal stem cells derived from diabetic rats (drBMSCs) in vitro, and to evaluate the effect of MF on the ectopic osteogenesis of drBMSCs in a nude mouse model in vivo. Methods: BMSCs were extracted from normal and diabetic rats. In vitro, a cell viability assay (Cell Counting Kit-8), tests of alkaline phosphatase (ALP) activity, and western blot analysis were first used to determine the cell proliferation and osteogenic differentiation of drBMSCs that were subjected to treatment with different concentrations of MF (0, 50, 100, 200, 500 μM). The cells were then divided into 5 groups: (1) normal rat BMSCs (the BMSCs derived from normal rats group), (2) the drBMSCs group, (3) the drBMSCs + Mito-TEMPO (10 μM, ROS scavenger) group, (4) the drBMSCs + MF (200 μM) group, and (5) the drBMSCs + MF (200 μM) + H2O2 (50 μM, ROS activator) group. Intracellular ROS detection, a senescenceassociated β-galactosidase assay, ALP staining, alizarin red staining, western blotting, and immunofluorescence assays were performed to determine the effects of MF on oxidative stress and osteogenic differentiation in drBMSCs. In vivo, the effect of MF on the ectopic osteogenesis of drBMSCs was evaluated in a nude mouse model. Results: MF effectively reduced ROS levels in drBMSCs. The cell proliferation, ALP activity, mineral deposition, and osteogenic-related protein expression of drBMSCs were demonstrably higher in the MF-treated group than in the non-MF-treated group. H2O2 inhibited the effects of MF. In addition, ectopic osteogenesis was significantly increased in drBMSCs treated with MF. Conclusions: MF promoted the proliferation and osteogenic differentiation of drBMSCs by inhibiting the oxidative stress induced by diabetes and enhenced the ectopic bone formation of drBMSCs in nude mice.
Abstract
Purpose: The purpose of this study was to determine whether metformin (MF) could alleviate the expresssion of reactive oxygen species (ROS) and improve the osteogenic ability of bone marrow mesenchymal stem cells derived from diabetic rats (drBMSCs) in vitro, and to evaluate the effect of MF on the ectopic osteogenesis of drBMSCs in a nude mouse model in vivo. Methods: BMSCs were extracted from normal and diabetic rats. In vitro, a cell viability assay (Cell Counting Kit-8), tests of alkaline phosphatase (ALP) activity, and western blot analysis were first used to determine the cell proliferation and osteogenic differentiation of drBMSCs that were subjected to treatment with different concentrations of MF (0, 50, 100, 200, 500 μM). The cells were then divided into 5 groups: (1) normal rat BMSCs (the BMSCs derived from normal rats group), (2) the drBMSCs group, (3) the drBMSCs + Mito-TEMPO (10 μM, ROS scavenger) group, (4) the drBMSCs + MF (200 μM) group, and (5) the drBMSCs + MF (200 μM) + H2O2 (50 μM, ROS activator) group. Intracellular ROS detection, a senescenceassociated β-galactosidase assay, ALP staining, alizarin red staining, western blotting, and immunofluorescence assays were performed to determine the effects of MF on oxidative stress and osteogenic differentiation in drBMSCs. In vivo, the effect of MF on the ectopic osteogenesis of drBMSCs was evaluated in a nude mouse model. Results: MF effectively reduced ROS levels in drBMSCs. The cell proliferation, ALP activity, mineral deposition, and osteogenic-related protein expression of drBMSCs were demonstrably higher in the MF-treated group than in the non-MF-treated group. H2O2 inhibited the effects of MF. In addition, ectopic osteogenesis was significantly increased in drBMSCs treated with MF. Conclusions: MF promoted the proliferation and osteogenic differentiation of drBMSCs by inhibiting the oxidative stress induced by diabetes and enhenced the ectopic bone formation of drBMSCs in nude mice.
참고문헌 (37)
- American Diabetes Association, "2. Classification and diagnosis of diabetes : Standards of Medical Care in Diabetes-2021", Diabetes Care, 44, pp.S15~S33 (2021)
- Alasqah MN, "Peri-implant soft tissue status and crestal bone levels around adjacent implants placed in patients with and without type-2 diabetes mellitus : 6 years follow-up results", Clin Implant Dent Relat Res, 20, pp.562~568 (2018)
- Wang X, "Current knowledge regarding the interaction between oral bone metabolic disorders and diabetes mellitus", Front Endocrinol(Lausanne), 11, pp.536~ (2020)
- Wu YY, "Diabetes mellitus related bone metabolism and periodontal disease", Int J Oral Sci, 7, pp.63~72 (2015)
- Sakkas A, "Autogenous bone grafts in oral implantology-is it still a “gold standard”? A consecutive review of 279 patients with 456 clinical procedures", Int J Implant Dent, 3, pp.23~ (2017)
- Proussaefs P, "The use of intraorally harvested autogenous block grafts for vertical alveolar ridge augmentation : a human study", Int J Periodontics Restorative Dent, 25, pp.351~363 (2005)
- Sakkas A, "A clinical study of the outcomes and complications associated with zygomatic buttress block bone graft for limited preimplant augmentation procedures", J Craniomaxillofac Surg, 44, pp.249~256 (2016)
- Ladha K, "Bone augmentation as an adjunct to dental implant rehabilitation in patients with diabetes mellitus : a review of literature", Natl J Maxillofac Surg, 8, pp.95~101 (2017)
- Gjerde C, "Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial", Stem Cell Res Ther, 9, pp.213~ (2018)
- Salgado AJ, "Bone tissue engineering : state of the art and future trends", Macromol Biosci, 4, pp.743~765 (2004)
- Yousefi AM, "Prospect of stem cells in bone tissue engineering : a review", Stem Cells Int, 2016, pp.6180487~ (2016)
- Pittenger MF, "Multilineage potential of adult human mesenchymal stem cells", Science, 284, pp.143~147 (1999)
- Xu L, "Tissue source determines the differentiation potentials of mesenchymal stem cells : a comparative study of human mesenchymal stem cells from bone marrow and adipose tissue", Stem Cell Res Ther, 8, pp.275~ (2017)
- Colombo JS, "Delayed osteoblast differentiation and altered inflammatory response around implants placed in incisor sockets of type 2 diabetic rats", Clin Oral Implants Res, 22, pp.578~586 (2011)
- Olekson MP, "Soluble receptor for advanced glycation end products improves stromal cell-derived factor-1 activity in model diabetic environments", Adv Wound Care(New Rochelle), 5, pp.527~538 (2016)
- Piscitelli P, "Diabetes and bone : biological and environmental factors", Curr Opin Endocrinol Diabetes Obes, 22, pp.439~445 (2015)
- Qiu X, "Melatonin rescued reactive oxygen species-impaired osteogenesis of human bone marrow mesenchymal stem cells in the presence of tumor necrosis factor-alpha", Stem Cells Int, 2019, pp.6403967~ (2019)
- Lv Z, "Metformin and its benefits for various diseases", Front Endocrinol(Lausanne), 11, pp.191~ (2020)
- Shaik AR, "Metformin : Is It the well wisher of bone beyond glycemic control in diabetes mellitus?", Calcif Tissue Int, 108, pp.693~707 (2021)
- Lin J, "Metformin promotes the osseointegration of titanium implants under osteoporotic conditions by regulating BMSCs autophagy, and osteogenic differentiation", Biochem Biophys Res Commun, 531, pp.228~235 (2020)
- Sun R, "Effects of metformin on the osteogenesis of alveolar BMSCs from diabetic patients and implant osseointegration in rats", Oral Dis, 28, pp.1170~1180 (2022)
- Aung M, "The future of metformin in the prevention of diabetes-related osteoporosis", Cureus, 12, pp.e10412~ (2020)
- Reed MJ, "A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat", Metabolism, 49, pp.1390~1394 (2000)
- Yin D, "Effect of mussel adhesive protein coating on osteogenesis in vitro and osteointegration in vivo to alkali-treated titanium with nanonetwork structures", Int J Nanomedicine, 14, pp.3831~3843 (2019)
- Qiao Q, "Semaphorin 3A promotes osteogenic differentiation of BMSC from type 2 diabetes mellitus rats", J Mol Histol, 49, pp.369~376 (2018)
- Pallag A, "Equisetum arvense L. extract induces antibacterial activity and modulates oxidative stress, inflammation, and apoptosis in endothelial vascular cells exposed to hyperosmotic stress", Oxid Med Cell Longev, 2018, pp.3060525~ (2018)
- Ma Q, "Role of Nrf2 in oxidative stress and toxicity", Annu Rev Pharmacol Toxicol, 53, pp.401~426 (2013)
- Feng YF, "Effect of reactive oxygen species overproduction on osteogenesis of porous titanium implant in the present of diabetes mellitus", Biomaterials, 34, pp.2234~2243 (2013)
- Ait-Aissa K, "Mitochondrial oxidative phosphorylation defect in the heart of subjects with coronary artery disease", Sci Rep, 9, pp.7623~ (2019)
- Hu XF, "Adiponectin improves the osteointegration of titanium implant under diabetic conditions by reversing mitochondrial dysfunction via the AMPK pathway in vivo and in vitro", Acta Biomater, 61, pp.233~248 (2017)
- Gan X, "The potential role of damage-associated molecular patterns derived from mitochondria in osteocyte apoptosis and bone remodeling", Bone, 62, pp.67~68 (2014)
- Zheng J, "Metformin use and risk of gastric adenocarcinoma in a Swedish population-based cohort study", Br J Cancer, 121, pp.877~882 (2019)
- Bahrambeigi S, "Metformin; an old antidiabetic drug with new potentials in bone disorders", Biomed Pharmacother, 109, pp.1593~1601 (2019)
- Nguyen C, "Exploiting mitochondrial vulnerabilities to trigger apoptosis selectively in cancer cells", Cancers(Basel), 11, pp.916~ (2019)
- Gao Y, "Metformin regulates osteoblast and adipocyte differentiation of rat mesenchymal stem cells", J Pharm Pharmacol, 60, pp.1695~1700 (2008)
- Zhen D, "Metformin reverses the deleterious effects of high glucose on osteoblast function", J Diabetes Complications, 24, pp.334~344 (2010)
- Kulkarni AS, "Benefits of metformin in attenuating the hallmarks of aging", Cell Metab, 32, pp.15~30 (2020)